Ayşe UYSAL, Nur Akad SOYER, Melda ÖZKAN, Fahri ŞAHİN, Filiz VURAL, Mahmut TÖBÜ, Murat TOMBULOĞLU, Güray SAYDAM

Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience

Öz Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone. Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 and January 2016 were screened. The patients were followed until March 2016 after CFZ treatment. Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. The median age was 62 (47-76) years. The median number of prior treatment lines was 3 (2-7). The median number of administered cycles of treatment for CFZ was 4 (1-10). The median overall response rate was 26.3%. The most common hematological adverse events were anemia and thrombocytopenia (38%). The most common nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient died because of pneumonia during the treatment period. The median duration of response rate and time to next therapy were 8 (7-9) and 3 (2-16) months, respectively. The median overall survival was 8 (0.5-33) months. Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreated R/R-MM patients.

Anahtar Kelimeler:

Multiple myeloma, carfilzomib, proteasome inhibitors, novel therapies

Tam Metin

Kaynak Göster

Bibtex	`@ { tbtkmedical576468, journal = {Turkish Journal of Medical Sciences}, issn = {1300-0144}, eissn = {1303-6165}, address = {}, publisher = {TÜBİTAK}, year = {2018}, volume = {48}, pages = {80 - 83}, doi = {}, title = {Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience}, key = {cite}, author = {Uysal, Ayşe and Soyer, Nur Akad and Özkan, Melda and Şahin, Fahri and Vural, Filiz and Töbü, Mahmut and Tombuloğlu, Murat and Saydam, Güray} }`
APA	Uysal, A , Soyer, N , Özkan, M , Şahin, F , Vural, F , Töbü, M , Tombuloğlu, M , Saydam, G . (2018). Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience . Turkish Journal of Medical Sciences , 48 (1) , 80-83 . Retrieved from https://dergipark.org.tr/tr/pub/tbtkmedical/issue/45691/576468
MLA	Uysal, A , Soyer, N , Özkan, M , Şahin, F , Vural, F , Töbü, M , Tombuloğlu, M , Saydam, G . "Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience" . Turkish Journal of Medical Sciences 48 (2018 ): 80-83 <https://dergipark.org.tr/tr/pub/tbtkmedical/issue/45691/576468>
Chicago	Uysal, A , Soyer, N , Özkan, M , Şahin, F , Vural, F , Töbü, M , Tombuloğlu, M , Saydam, G . "Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience". Turkish Journal of Medical Sciences 48 (2018 ): 80-83
RIS	TY - JOUR T1 - Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience AU - Ayşe Uysal , Nur Akad Soyer , Melda Özkan , Fahri Şahin , Filiz Vural , Mahmut Töbü , Murat Tombuloğlu , Güray Saydam Y1 - 2018 PY - 2018 N1 - DO - T2 - Turkish Journal of Medical Sciences JF - Journal JO - JOR SP - 80 EP - 83 VL - 48 IS - 1 SN - 1300-0144-1303-6165 M3 - UR - Y2 - 2021 ER -
EndNote	%0 Turkish Journal of Medical Sciences Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience %A Ayşe Uysal , Nur Akad Soyer , Melda Özkan , Fahri Şahin , Filiz Vural , Mahmut Töbü , Murat Tombuloğlu , Güray Saydam %T Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience %D 2018 %J Turkish Journal of Medical Sciences %P 1300-0144-1303-6165 %V 48 %N 1 %R %U
ISNAD	Uysal, Ayşe , Soyer, Nur Akad , Özkan, Melda , Şahin, Fahri , Vural, Filiz , Töbü, Mahmut , Tombuloğlu, Murat , Saydam, Güray . "Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience". Turkish Journal of Medical Sciences 48 / 1 (Şubat 2018): 80-83 .
AMA	Uysal A , Soyer N , Özkan M , Şahin F , Vural F , Töbü M , Tombuloğlu M , Saydam G . Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience. Turkish Journal of Medical Sciences. 2018; 48(1): 80-83.
Vancouver	Uysal A , Soyer N , Özkan M , Şahin F , Vural F , Töbü M , Tombuloğlu M , Saydam G . Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience. Turkish Journal of Medical Sciences. 2018; 48(1): 80-83.
IEEE	A. Uysal , N. Soyer , M. Özkan , F. Şahin , F. Vural , M. Töbü , M. Tombuloğlu ve G. Saydam , "Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience", Turkish Journal of Medical Sciences, c. 48, sayı. 1, ss. 80-83, Şub. 2018